Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group., G F. Gjerset, M C. Pike, J W. Mosley, J Hassett, Mary A. Fletcher, E Donegan, J W. Parker, R B. Counts, Y Zhou, C K. Kasper
Faculty Articles